{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T08:34:19Z","timestamp":1782808459544,"version":"3.54.5"},"reference-count":42,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.jacc.2020.12.053","type":"journal-article","created":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T16:25:26Z","timestamp":1614615926000},"page":"1197-1207","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial Fibrillation"],"prefix":"10.1016","volume":"77","author":[{"given":"Jan","family":"Steffel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian T.","family":"Ruff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ophelia","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Braunwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong-Gun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina A.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Connolly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliott M.","family":"Antman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Giugliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2020.12.053_bib1","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2020.12.053_bib2","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2020.12.053_bib3","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2020.12.053_bib4","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2020.12.053_bib5","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2020.12.053_bib6","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"386","author":"Giugliano","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2020.12.053_bib7","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jacc.2019.01.011","volume":"74","author":"January","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.12.053_bib8","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS)","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2020.12.053_bib9","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.amjmed.2016.02.028","article-title":"Mortality in patients with atrial fibrillation randomized to edoxaban or warfarin: insights from the ENGAGE AF-TIMI 48 trial","volume":"129","author":"Giugliano","year":"2016","journal-title":"Am J Med"},{"key":"10.1016\/j.jacc.2020.12.053_bib10","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2020.12.053_bib11","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s12471-019-1267-9","article-title":"Inappropriate non-vitamin K antagonist oral anticoagulants prescriptions: be cautious with dose reductions","volume":"27","author":"Jacobs","year":"2019","journal-title":"Neth Heart J"},{"key":"10.1016\/j.jacc.2020.12.053_bib12","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1016\/j.jacc.2016.09.966","article-title":"Off-label dosing of non-vitamin k antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II Registry","volume":"68","author":"Steinberg","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.12.053_bib13","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/j.jacc.2020.07.045","article-title":"Mortality in patients with atrial fibrillation receiving nonrecommended doses of direct oral anticoagulants","volume":"76","author":"Camm","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.12.053_bib14","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.jacc.2020.08.001","article-title":"Direct oral anticoagulant dosing: truth or Consequences","volume":"76","author":"Naccarelli","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.12.053_bib15","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1016\/S0140-6736(14)61943-7","article-title":"Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial","volume":"385","author":"Ruff","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2020.12.053_bib16","doi-asserted-by":"crossref","first-page":"297","DOI":"10.7326\/0003-4819-151-5-200909010-00003","article-title":"The net clinical benefit of warfarin anticoagulation in atrial fibrillation","volume":"151","author":"Singer","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2020.12.053_bib17","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.ahj.2010.06.042","volume":"160","author":"Ruff","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2020.12.053_bib18","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"Schulman","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jacc.2020.12.053_bib19","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/003693305700200504","article-title":"Cerebral vascular accidents in patients over the age of 60. II. Prognosis","volume":"2","author":"Rankin","year":"1957","journal-title":"Scot Med J"},{"key":"10.1016\/j.jacc.2020.12.053_bib20","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1161\/CIRCULATIONAHA.118.033933","article-title":"Linking endogenous factor Xa activity, a biologically relevant pharmacodynamic marker, to edoxaban plasma concentrations and clinical outcomes in the ENGAGE AF-TIMI 48 Trial","volume":"138","author":"Yin","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2020.12.053_bib21","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1056\/NEJMoa2012883","article-title":"Low-dose edoxaban in very elderly patients with atrial fibrillation","volume":"383","author":"Okumura","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2020.12.053_bib22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2020.12.053_bib23","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2020.12.053_bib24","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1161\/CIRCULATIONAHA.120.046048","article-title":"The COMPASS trial: net clinical benefit of low-dose rivaroxaban plus aspirin as compared with aspirin in patients with\u00a0chronic vascular disease","volume":"142","author":"Steffel","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2020.12.053_bib25","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1161\/CIRCULATIONAHA.117.033442","article-title":"Is there really a benefit to net clinical benefit in testing antithrombotics?","volume":"137","author":"Steg","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2020.12.053_bib26","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1002\/clc.22971","article-title":"Atrial fibrillation patient preferences for oral anticoagulation and stroke knowledge: results of a conjoint analysis","volume":"41","author":"Lane","year":"2018","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.jacc.2020.12.053_bib27","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40271-016-0185-9","article-title":"Patient preferences for oral anticoagulation therapy in atrial fibrillation: a systematic literature review","volume":"10","author":"Wilke","year":"2017","journal-title":"Patient"},{"key":"10.1016\/j.jacc.2020.12.053_bib28","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1160\/TH11-08-0566","article-title":"Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation","volume":"107","author":"Salazar","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2020.12.053_bib29","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2020.12.053_bib30","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s11239-020-02055-1","article-title":"DOAC compared to LMWH in the treatment of cancer related-venous thromboembolism: a systematic review and meta-analysis","volume":"50","author":"Mai","year":"2020","journal-title":"J\u00a0Thromb Thrombolysis"},{"key":"10.1016\/j.jacc.2020.12.053_bib31","article-title":"Efficacy and safety of edoxaban in patients with active malignancy and atrial fibrillation: analysis of the ENGAGE AF - TIMI 48 Trial","volume":"7","author":"Fanola","year":"2018","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacc.2020.12.053_bib32","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.amjmed.2017.06.026","article-title":"Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and a history of cancer: insights from the ARISTOTLE Trial","volume":"130","author":"Melloni","year":"2017","journal-title":"Am J Med"},{"key":"10.1016\/j.jacc.2020.12.053_bib33","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.jacc.2016.06.034","article-title":"Edoxaban versus warfarin in atrial fibrillation patients at risk of falling: ENGAGE AF-TIMI 48 analysis","volume":"68","author":"Steffel","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.12.053_bib34","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1200\/JCO.2001.19.5.1519","article-title":"Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology","volume":"19","author":"Schiffer","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jacc.2020.12.053_bib35","doi-asserted-by":"crossref","first-page":"265","DOI":"10.21037\/apm.2017.11.01","article-title":"Bleeding in cancer patients and its treatment: a review","volume":"7","author":"Johnstone","year":"2018","journal-title":"Ann Palliat Med"},{"issue":"Suppl 2","key":"10.1016\/j.jacc.2020.12.053_bib36","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/S0049-3848(14)50009-6","article-title":"Bleeding complications during anticoagulant treatment in patients with cancer","volume":"133","author":"Kamphuisen","year":"2014","journal-title":"Thromb Res"},{"key":"10.1016\/j.jacc.2020.12.053_bib37","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1161\/CIRCULATIONAHA.119.041296","article-title":"Patients with atrial fibrillation taking nonsteroidal anti-inflammatory drugs and oral anticoagulants in the ARISTOTLE trial","volume":"141","author":"Dalgaard","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2020.12.053_bib38","article-title":"Frequency and outcomes of reduced dose non-vitamin k antagonist anticoagulants: results from ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II)","volume":"7","author":"Steinberg","year":"2018","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacc.2020.12.053_bib39","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/bcp.14127","article-title":"Impact of direct oral anticoagulant off-label doses on clinical outcomes of atrial fibrillation patients: a systematic review","volume":"86","author":"Santos","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jacc.2020.12.053_bib40","article-title":"Rates of potentially inappropriate dosing of direct-acting oral anticoagulants and associations with geriatric conditions among older patients with atrial fibrillation: the SAGE-AF study","volume":"9","author":"Sanghai","year":"2020","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacc.2020.12.053_bib41","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1056\/NEJMp1103050","article-title":"Anticoagulant options--why the FDA approved a higher but not a lower dose of dabigatran","volume":"364","author":"Beasley","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2020.12.053_bib42","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/j.jacc.2017.03.600","article-title":"Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction","volume":"69","author":"Yao","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109721000085?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109721000085?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:39:57Z","timestamp":1760017197000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109721000085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":42,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S0735109721000085"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2020.12.053","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial Fibrillation","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2020.12.053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}